MSI-1436 manufacturers
- MSI-1436;Trodusquemine
-
- $10.00
-
2026-06-08
- CAS:186139-09-3
- Min. Order: 1ASSAYS
- Purity: 99%
- Supply Ability: 1 ton
- MSI-1436
-
- $2550.00
-
2026-05-22
- CAS:186139-09-3
- Purity:
- Supply Ability: 10g
- MSI-1436
-
- $2550.00
-
2026-05-21
- CAS:186139-09-3
- Purity:
- Supply Ability: 10g
|
| | MSI-1436 Basic information |
| Product Name: | MSI-1436 | | Synonyms: | MSI-1436;TRODUSQUEMINE;AMINOSTEROL-1436;MSI1436;Cholestane-7,24-diol, 3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-, 24-(hydrogen sulfate), (3β,5α,7α,24R)-;Trodusquemine (MSI-1436);MSI-1436 USP/EP/BP;MSI-1436(Trodusquemine;MSI 1436,MSI1436;Trodusquemine | | CAS: | 186139-09-3 | | MF: | C37H72N4O5S | | MW: | 685.07 | | EINECS: | 202-303-5 | | Product Categories: | | | Mol File: | 186139-09-3.mol |  |
| | MSI-1436 Chemical Properties |
| density | 1.12±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C(protect from light) | | solubility | Soluble in DMSO | | pka | -3.49±0.18(Predicted) | | form | Solid | | color | White to yellow |
| | MSI-1436 Usage And Synthesis |
| Uses | Trodusquemine is a specific protein tyrosine phosphatase 1B (PTP1B) inhibitor. | | Uses | Treatment of medically significant obesity. | | Definition | ChEBI: Trodusquemine is a bile acid. | | in vivo | MSI-1436 (10 mg/kg, i.p.) causes obesity-dependent body weight, reduces total body fat content and adipocyte size and lipid content of white adipose tissue of mice. MSI-1436 treatment significantly reduces plasma insulin levels. MSI-1436 (10 mg/kg, i.p.) increases phosphorylation of STAT-3 2.7-fold and, in conjunction with 100 U/kg insulin, p-IRβ increases threefold over insulin alone-treated rats[1]. MSI-1436 (Trodusquemine) exhibits anxiolytic effect through a restoration of endocannabinoid (eCB) signaling within the amygdala[2]. MSI-1436 (5 mg/kg, i.p.) has an anti-diabetic effect on diabetic mice, and is sufficient to suppress food intake and cause weight loss in CD1 mice[3]. |
| | MSI-1436 Preparation Products And Raw materials |
|